Clinical Trials Browser

Phase 2 × Completed × Small Cell Lung Cancer Recurrent × Clear all

NCT03823118 2023-02-23

S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung Cancer

Phase 2 Completed

Small Cell Lung Cancer Recurrent